- Home
- CEE vs AGEN Comparison
CEE vs AGEN Comparison
Compare CEE & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEE | AGEN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 126.2M |
| IPO Year | 1994 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CEE | AGEN |
|---|---|---|
| Price | $17.49 | $3.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 23.5K | ★ 486.5K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $61.42 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $11.20 | $1.38 |
| 52 Week High | $19.98 | $7.34 |
Technical Indicators
Market Signals| Indicator | CEE | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 38.36 | 49.59 |
| Support Level | $16.97 | $2.91 |
| Resistance Level | $18.35 | $4.72 |
| Average True Range (ATR) | 0.69 | 0.27 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 12.10 | 38.97 |
Price Performance
Historical ComparisonAbout CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).